A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults

Launched by PFIZER · Jun 5, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at two different vaccines, called 20vPnC and 13vPnC, to see how safe and effective they are for preventing pneumococcal disease in adults aged 50 and older in China. Pneumococcal disease can lead to serious infections like pneumonia, so finding effective vaccines is important. The study will include healthy adults who haven't received any pneumococcal vaccines in the past.

To join the study, participants must be generally healthy, even if they have stable preexisting conditions. However, people who have had a serious infection caused by a specific bacteria, or who have received any pneumococcal vaccine before, cannot participate. If someone joins the study, they can expect to receive one of the vaccines and will be monitored for any side effects and how well their immune system responds. This study is still in the planning stage and has not started recruiting participants yet.

Gender

ALL

Eligibility criteria

• Key inclusion criteria:
• • 1.Generally healthy adults including those with preexisting stable disease determined to be eligible based on clinical assessment, medical history and clinical judgment.
• Key exclusion criteria:
• • 1. History of microbiologically-proven invasive disease caused by Streptococcus pneumoniae
• • 2. Previous vaccination with any licensed or investigational pneumococcal vaccine or planned receipt through study participation.